BOSTON, Mass. — Perceptive Imaging, a global leader in clinical trial imaging solutions, announced the appointment of Doug Fulling as Chief Executive Officer, effective October 1. He succeeds David Herron, who will transition to the role of Senior Advisor and continue serving on the company’s Board of Directors.
Fulling brings more than 25 years of leadership experience in the life sciences industry, including senior roles at Precision AQ, Symphony Health (an ICON Plc company), PRA Health Sciences, and MDS Pharma Services. His appointment marks the next phase of Perceptive Imaging’s growth strategy, focusing on expanding client services, driving innovation, and increasing operational capacity to support the clinical development needs of global pharmaceutical partners.
“Perceptive Imaging has undergone significant transformation in recent years and is strongly positioned to embark on the next chapter of the company’s development,” said Doug Fulling. “I have followed the company’s evolution for more than a decade and am very honored to join the Perceptive team at such an exciting time. I look forward to working with my new colleagues and our clients to deliver the imaging solutions and services needed to bring new medical treatments to patients sooner. As David Herron transitions to a Board role, we thank him for all the work he has done during his tenure as CEO to evolve Perceptive Imaging into a highly sophisticated healthcare platform with very exciting future prospects.”
David Herron, who has led Perceptive Imaging since 2022, expressed confidence in his successor. “We are very pleased to appoint an executive of Doug Fulling’s caliber to lead Perceptive Imaging into the future,” Herron said. “His wealth of experience and proven track record of scaling organizations with integrity and vision, along with all our people’s incredible expertise, knowledge and dedication, will leave Perceptive well positioned to realize our ambitious plans. I am incredibly proud of what the team and I have built together in recent years and excited for what lies ahead. I know Perceptive will continue to thrive under Doug’s leadership and look forward to supporting him and the team as a member of the Board.”
Perceptive Imaging’s client-focused operating model has fueled strong business growth and a robust pipeline of new studies. The company continues to serve top global pharmaceutical firms, having supported nearly 400 regulatory approvals as of June 30, 2025.
